Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid Tumors

Preclinical and clinical evidence suggests that intestinal low-dose radiotherapy (ILDR) may enhance antitumor immune responses by modulating the gut microenvironment, thereby improving the efficacy of immune checkpoint inhibitors (ICBs) in refractory solid tumors. Based on these findings, the investigators initiate a multicohort phase II clinical trial to evaluate the clinical benefit and safety of ILDR combined with PD-1/PD-L1 monoclonal antibody therapy in patients with metastatic solid tumors resistant to prior ICB treatment. In this study, patients are stratified into three parallel cohor

Trial Details

NCT ID
NCT07071103
Phase
PHASE2
Sponsor
Chuangzhen Chen
Status
RECRUITING
Cancer Type
Adenocarcinoma Esophageal Cancer
Interventions
  • Low-dose radiotherapy to the intestine (ILDR)
  • PD-1/PD-L1 monoclonal antibodies
Locations (sample)
  • Shantou, Guangdong, China|23.35489,116.67876

Key Eligibility Criteria

  • Age ≥18 years, ≤80 years, regardless of gender.
  • ECOG level 0-2.
  • Expected life span\>3 months.
  • At least one accessible and measurable lesion should be selected as the target lesion for observation according to RECIST criteria.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Esophageal Cancer Trials on Trialify →